For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.